Professor Sean Kehoe FRCOG, MA, MD, DCH, MB, BCh, BAO, BA

Professor Sean Kehoe

Institute of Cancer and Genomic Sciences
Lawson Tait Professor of Gynaecological Cancer

Contact details

Institute of Cancer and Genomic Sciences
Vincent Drive
University of Birmingham
Birmingham B15 2TT

Sean Kehoe is a clinical academic managing the treatment of gynaecological cancers and precancers in women. He has over 20 years experience in these areas. His clinical work is based at Birmingham City Hospital.


  • FRCOG 2005
  • MA Oxford University 2002
  • MD Trinity College Dublin 1998
  • DCH, Royal College of Surgeon of Ireland1985
  • MB BCh BAO BA Trinity College Dublin 1983


Sean Kehoe qualified at Trinity College Dublin and after obtaining his MRCOG came to the UK and took the post of CRC Fellow in Gynaecological Cancer at the University of Birmingham. He obtained an MD, and continued to work in Birmingham achieving subspecialty training in Gynaecological Oncology and was appointed a Senior Lecturer in Gynaecological Cancer.

He then moved to Oxford and as the Foundation Professor of Gynaecological Cancer he developed the Oxford Gynaecological Cancer Centre before returning to Birmingham to take up the Lawson Tait Chair in Gynaecological Cancer in December 2012.

He has lectured widely both nationally and internationally. In 2010 he was awarded the Boyle Memorial Medal by the Institute of Obstetricians and Gynaecologists of Ireland and was re-elected a Senior Research Fellow of St Peters College, Oxford in 2013.


  •  Senior Academy Teacher – Oncology, Birmingham City Hospital, Year 4 students
  • Clinical teaching of undergraduates and post-graduates

Postgraduate supervision

In previous positions – PhD/MSc students


Professor Kehoe's interests are in gynaecological cancer Clinical Trials. He has a major interest in ovarian cancer and the understanding of malignant changes which occur during therapy. (More ...)

Other activities

  • Chair of FIGO Cancer Committee – 2019-2022
  • Visiting Professor to Hong Kong University
  • Chair of Gynaecological Cancer Group, National Cancer Registry and Analysis Service, PHE
  • Member of the FIGO Cancer Committee (International Federation of Gynaecology and Obstetrics)
  • Senior Research Fellow, St Peters College, University of Oxford (2013 - present)
  • Senior Medical Advisor/spokesperson and Trustee of OVACOME, national ovarian cancer charity (2008 - present)
  • President of the British Gynaecological Cancer Society (2009 - 2013)
  • Member of the National Cancer Intelligence Network - Gynaecological Oncology

RCOG Activities

  • Member of the Lindsay Park Audit Committee (2016- present)
  • Member of the Royal College of Surgeons Cancer Services Committee (2010 - present)
  • Council Member of the RCOG (2011 - 2013)
  • Convener  of Study Group Meetings RCOG (2008 - 2013)
  • SST Committee (2013 - present)
  • Representative for the British Association of Surgical Oncology
  • Representative on the Cancer Early Diagnostic Group, Department of Health


  • Senior Medical Advisor/spokesperson and Trustee of OVACOME, ovarian cancer National Charity (2008 - present)
  • Volunteer Specialist for the Swinfen Charitable Trust (2007 - present)
  • Member of the Executive Advisory board for IFMCH – (International Foundation for Women and Child Health) (2009 - present)

Editorial Work

  • Editorial Board: British Journal of Obstetrics & Gynaecology – (2008 - present)
  • Editorial Board: Chinese Medical Journal (2011 – present)
  • Editorial Board: Gynaecologic Oncology (2005 – 2008)
  • Advisory Editor: European Journal of Surgical Oncology (2004 - 2008)
  • Associate Editor: European Journal of Surgical Oncology (2008 – 2009)
  • Editorial Board: European Journal of Obstetrics, Gynaecology & Reproductive Medicine (2005 – present) [Advisory Editor: 2006 - 2011]


Comparison of survival outcome of patients with primary peritoneal and fallopian tube carcinoma treated with neoadjuvant chemotherapy versus primary debulking surgery. Soleymani Majd H, Ismail L, Hardern K, Ferrari F, Kehoe S. J Obstet Gynaecol. 2016 Dec 15:1-4.

Olaparib and ovarian cancer-overall survival outcomes. Kehoe S. Lancet Oncol. 2016 Nov;17(11):1474-1475

Over-expression of DNMT3A predicts the risk of recurrent vulvar squamous cell carcinomas. Leonard S, Pereira M, Fox R, Gordon N, Yap J, Kehoe S, Luesley D, Woodman C, Ganesan R. Gynecol Oncol. 2016 Nov;143(2):414-420

Routine Intraoperative Frozen Section Examination to Minimize Bimodal Treatment in Early-Stage Cervical Cancer. Gubbala PK, Laios A, Wang Z, Dhar S, Pathiraja PJ, Haldar K, Kehoe ST. Int J Gynecol Cancer. 2016 Jul;26(6):1148-53

Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues…. Leary A, Cowan R, Chi D, Kehoe S, Nankivell M. Am Soc Clin Oncol Educ Book. 2016;35:153-62.

Patient-Reported Outcomes After Extensive (Ultraradical) Surgery for Ovarian Cancer: Results From a Prospective Longitudinal Feasibility Study. Soo Hoo S, Marriott N, Houlton A, Nevin J, Balega J, Singh K, Yap J, Sethuram R, Elattar A, Luesley D, Kehoe S, Sundar S. Int J Gynecol Cancer. 2015 Nov;25(9):1599-607

When is it safe to omit surgery in primary peritoneal cancer with small volume disease? Pounds R, Kehoe S. Curr Oncol Rep. 2015 Aug;17(8):36.

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Lancet. 2015 Jul 18;386(9990):249-57

Ganesan R, Brown LJ, Kehoe S, McCluggage WG, El-Bahrawy MA (2013), The role of frozen sections in gynaecological oncology: survey of practice in the United Kingdom. European Journal of Obstetrics, Gynaecology & Reproductive Biology. Feb: 166(2): 204-8

Ed. Keith-Edmonds (2012) Dewhurst's Textbook of Obstetrics and Gynaecology, 8th edWiley Blackwell Endometrial Cancer, ch 58, 776 Wiley Blackwell Endometrial Cancer, ch 58, 776

Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison (2011) Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2011 Oct 5;(10), Morrison (2011) Syst Rev. 2011 Oct 5;(10)

Shaw R, Luesley D, Monga A (2011). Shaws Textbook of Gynaecology 4th Edition, Churchill Livingston, Ovarian and Fallopian tube cancer ,ch 45, 678

Gaitskel Kl, Martinek I, Bryant A, Kehoe S, Shibani Nicum S, Morrison J(2011) Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev.  Sep 7;9:CD007930

Butler J, Barton D, Shepherd J, Reynolds K, Kehoe S. (2011) Gynaecological examinations. Good not bad medicine. British Medical Journal, Mar 23, 342

Aggarwal P, Kehoe S (2011) Ovarian tumours in pregnancy: a literature review. European Journal of Obstetrics, Gynaecology and Reproductive Biology. Apr; 155(2):119-24. . Apr; 155(2):119-24.

McCluggage WG, Hirschowitz L, Ganesan R, Kehoe S, Nordin A (2010), Which staging system to use for gynaecological cancers: Recommendations for practice in the United Kingdom. International Journal of Gynaecological  Cancer. Nov: 20(8):1301-2 Nov: 20(8):1301-2

View all publications in research portal


Ovarian Cancer/Surgery